Last reviewed · How we verify
Cetuximab-Zr. 89
At a glance
| Generic name | Cetuximab-Zr. 89 |
|---|---|
| Sponsor | Maastricht Radiation Oncology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetuximab-Zr. 89 CI brief — competitive landscape report
- Cetuximab-Zr. 89 updates RSS · CI watch RSS
- Maastricht Radiation Oncology portfolio CI